Drug Information

Drug General Information
Drug ID
D0JR0G
Former ID
DNC010736
Drug Name
(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530823]
Structure
Download
2D MOL

3D MOL
Formula
C16H10ClN3O3
Canonical SMILES
C1=CC2=C(C=C1O)C(=C(N2)C3=C4C=C(C=CC4=NC3=O)Cl)NO
InChI
1S/C16H10ClN3O3/c17-7-1-3-11-9(5-7)13(16(22)19-11)15-14(20-23)10-6-8(21)2-4-12(10)18-15/h1-6,18,20-21,23H
InChIKey
BHEIFKJZVLZSDM-UHFFFAOYSA-N
PubChem Compound ID
46222245
Target and Pathway
Target(s) G1/S-specific cyclin E1 Target Info Inhibitor [530823]
Cell division protein kinase 2 Target Info Inhibitor [530823]
KEGG Pathway Cell cycle
Oocyte meiosis
p53 signaling pathway
PI3K-Akt signaling pathway
Hepatitis B
Measles
Pathways in cancer
Viral carcinogenesis
MicroRNAs in cancer
Prostate cancer
Small cell lung cancerhsa04068:FoxO signaling pathway
Progesterone-mediated oocyte maturation
Herpes simplex infection
Epstein-Barr virus infection
Small cell lung cancer
NetPath Pathway IL2 Signaling Pathway
TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
PANTHER Pathway Cell cycle
Parkinson disease
p53 pathway
p53 pathway feedback loops 2P00059:p53 pathway
p53 pathway feedback loops 2
Pathway Interaction Database Signaling events mediated by PRL
E2F transcription factor network
mTOR signaling pathway
FOXM1 transcription factor network
BARD1 signaling events
PLK3 signaling events
Regulation of retinoblastoma proteinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
p73 transcription factor network
ATR signaling pathway
IL2-mediated signaling events
FoxO family signaling
p53 pathway
Regulation of retinoblastoma protein
Reactome E2F mediated regulation of DNA replication
G0 and Early G1
SCF(Skp2)-mediated degradation of p27/p21
DNA Damage/Telomere Stress Induced Senescence
Cyclin E associated events during G1/S transition
G1/S-Specific Transcription
p53-Dependent G1 DNA Damage ResponseR-HSA-1538133:G0 and Early G1
Activation of ATR in response to replication stress
Regulation of APC/C activators between G1/S and early anaphase
Senescence-Associated Secretory Phenotype (SASP)
Processing of DNA double-strand break ends
G2 Phase
Orc1 removal from chromatin
Cyclin A/B1 associated events during G2/M transition
p53-Dependent G1 DNA Damage Response
Cyclin A:Cdk2-associated events at S phase entry
Meiotic recombination
Factors involved in megakaryocyte development and platelet production
WikiPathways DNA Damage Response
ID signaling pathway
G1 to S cell cycle control
Retinoblastoma (RB) in Cancer
Integrated Pancreatic Cancer Pathway
Parkinsons Disease Pathway
Parkin-Ubiquitin Proteasomal System pathway
Signaling Pathways in Glioblastoma
TSH signaling pathway
Mitotic G1-G1/S phases
Cell Cycle
miRNAs involved in DNA damage response
miRNA Regulation of DNA Damage Response
Androgen receptor signaling pathwayWP707:DNA Damage Response
DNA Replication
M/G1 Transition
S Phase
Meiotic Recombination
Aryl Hydrocarbon Receptor
ATM Signaling Pathway
Spinal Cord Injury
Oncostatin M Signaling Pathway
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Synthesis of DNA
Regulation of DNA replication
Mitotic G2-G2/M phases
Factors involved in megakaryocyte development and platelet production
APC/C-mediated degradation of cell cycle proteins
Cell Cycle Checkpoints
References
Ref 530823J Med Chem. 2010 May 13;53(9):3696-706.5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
Ref 530823J Med Chem. 2010 May 13;53(9):3696-706.5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.